Sharecafe

Mesoblast (ASX:MSB) – Webinar Presentation

Silviu Itescu - Managing Director & CEO - Mesoblast Limited (ASX:MSB) is developing innovative allogeneic cellular medicines to treat complex inflammatory diseases. The company’s portfolio of Phase 3 product candidates includes therapies for acute graft versus host disease, chronic heart failure and chronic low back pain.

 

Silviu Itescu – Managing Director & CEO – Mesoblast Limited (ASX:MSB) is developing innovative allogeneic cellular medicines to treat complex inflammatory diseases. The company’s portfolio of Phase 3 product candidates includes therapies for acute graft versus host disease, chronic heart failure and chronic low back pain.

Serving up fresh finance news, marker movers & expertise.
LinkedIn
Email
X

All Categories